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Introduction
Discussion
Respiratory infections are the
leading cause of mortality
globally. The advent of the
SARS-CoV-2 pandemic has
claimed over 4 million lives and
many more are suffering
sequelae post-infection. The past
year has shown us that there is a
pressing need for improved
treatments and symptomatic
management of viral respiratory
infections.
Preliminary studies in HBEC3-KT
cells have demonstrated that
Pam2/ODN (Pam2CSK4 and
ODN M362) results in overall
increased reactive oxygen
species (ROS) activity.
We used Influenza A Virus (IAV),
an orthomyxovirus, and Mouse
Hepatitis Virus (MHV), a
coronavirus, in this study
because of the differential
responses seen in infected cells.
For example, Coronaviruses are
known to inhibit the RIG-I
pathway, thereby suppressing
maximal interferon response.
Observing the differences in
responses could help us
understand the mechanism of






In HBECs, no change in the expression of
genes that promote antioxidant pathways
(NFE2L2) was observed while the
expression of inhibitors of those same
pathways (KEAP1) was elevated. This leads
to an overall increase in the activity of ROS,
bolstering defense against viral and other
intracellular pathogens. Interestingly enough,
we do not see any expression of these
genes in MLEs at baseline, regardless of
treatment (Figure 1).
There is a slight upward trend in the
expression of Cxcl10 (CXCL10) in HBECs 6
hours post Pam2/ODN treatment, we don’t
see any significant trends in MLEs.
In MLEs, we have shown that acutely,
Pam2/ODN decreases the expression of
Nfkbia (IkBa), an inhibitor of NF-kB. We
hypothesize this could be partially
responsible for the protective phenotype
described in previous studies. Importantly,
we do not see this result replicated in
HBECs (Figure 2).
We see significant decrease in IAV NP RNA
in IAV-infected HBECs treated with
Pam2/ODN. Conversely, we see an increase
in the expression of CXCL10, which falls in
line with the anticipated enhanced immune
response. Finally, we don’t observe a
difference in the expression of NFKBIA.
We see a slight downward trend in IAV NP
RNA expression in IAV-infected MLEs
treated with Pam2/ODN, although the
difference is not significant. A similar trend
can be seen in Cxcl10, which may be an
incidental finding (Figure 3).
In MHV-infected MLEs, we see no significant
changes in the expression of Ifng (IFN-g),
Nfkbia, Cxcl10, or MHV S protein after
treatment with Pam2/ODN compared to
PBS. This is most likely attributed to the
limited inoculation time of 24 hours. Previous
studies have shown significant changes in
expression at 72-hour timepoints post-
infection (Figure 4).
We anticipated a differential response in
gene expression between different cell types
after treatment with Pam2/ODN; HBECs are
bronchiolar cells while MLEs are more akin
to alveolar cells, which could suggest there
is a differential response dependent on cell
type.
Pam2/ODN presents a novel means to
combat viral pneumonia. Prophylactic
administration preferentially promotes
CXCL10 activity in IAV-infected HBECs while
downregulating inhibitors of NF-kB in
uninfected MLEs. Overall, this study validates
the protective phenotype observed in MLE-15
and HBEC3-KT cells while also pointing
towards a differential mechanism for the
observed phenotype.
Ware, H. H., Kulkarni, V. V., Wang, Y., Pantaleón García, J., Leiva
Juarez, M., Kirkpatrick, C. T., Wali, S., Syed, S., Kontoyiannis, A.
D., Sikkema, W., Tour, J. M., & Evans, S. E. (2019). Inducible lung
epithelial resistance requires multisource reactive oxygen species
generation to protect against bacterial infections. PloS one, 14(2),
e0208216. https://doi.org/10.1371/journal.pone.0208216
Figure 1: NFE2L2 and KEAP1 expression in treated HBECs and MLEs as 
a percentage of expression in untreated controls. Uninfected cells were 
treated with either PBS or Pam2/ODN (2.2 μM/0.55 μM)  for 4 hours.
Figure 2: Uninfected cells treated for 2, 4, and 6 hours with Pam2/ODN as 
a percentage of expression in untreated controls
Figure 4: MLE-15 cells treated with or without Pam2/ODN as a percentage of 
expression in uninfected controls. Cells were treated for 4 hours prior to inoculation 
with MHV-A59 at a multiplicity of infection (MOI) of 0.1 for 24 hours.
Figure 3: MLE-15 and HBEC3-KT cells treated with or without Pam2/ODN (2.2 
μM/0.55 μM) as a percentage of expression in uninfected controls. Cells were treated 
for 4 hours prior to inoculation with IAV-H3N2 at a multiplicity of infection (MOI) of 0.1 
for 24 hours.
